Compare SKE & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKE | BLLN |
|---|---|---|
| Founded | 1979 | 2016 |
| Country | Canada | United States |
| Employees | 170 | 713 |
| Industry | Precious Metals | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.9B |
| IPO Year | 2017 | N/A |
| Metric | SKE | BLLN |
|---|---|---|
| Price | $30.28 | $98.77 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $126.71 |
| AVG Volume (30 Days) | 509.1K | ★ 702.9K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $46.29 |
| Revenue Next Year | $37,573.35 | $30.14 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.12 | $61.96 |
| 52 Week High | $38.77 | $138.70 |
| Indicator | SKE | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 48.61 | 61.90 |
| Support Level | $28.14 | $79.07 |
| Resistance Level | $34.86 | $107.00 |
| Average True Range (ATR) | 1.46 | 7.80 |
| MACD | -0.15 | 0.91 |
| Stochastic Oscillator | 33.43 | 71.51 |
Skeena Resources Ltd is a mining company in development stage focusing on the construction and development of the Eskay Creek project in British Columbia. Eskay Creek is the next global gold development project and represents one of the highest-grade and lowest-cost open-pit precious metals mines, with substantial silver by-product production.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.